Investment Director and making a difference
- Yuexin joined Andera Life Sciences as investment director in 2021.
- Before joining Andera, Yuexin was vice president at 3H Health Investment Management Hong Kong and Shanghai where he made leading contributions to biotech portfolio including InnoCare Pharma (9969.HK), Keymed Biosciences (2162.HK) and EdiGene. His sector and management perspectives form through collaborations with entrepreneurs over the years, and earlier through life-cycle management at Merck, business development at Biotheranostics and investment research at Mérieux Développement.
- Yuexin holds PharmD from Shanghai Jiao Tong University and MSc in Management from HEC.
- Yuexin speaks Chinese, English and French.
42 is a new school
Investments of Yuexin
Clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension
Antibody drug conjugates for the treatment of cancer
Biotechnology company focused on developing improved treatments for thrombotic diseases
Developing therapeutic peptides for rare endocrine and related diseases
Biopharmaceutical company developing innovative therapies in the field of chronic inflammation